# The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia

> **NCT03944109** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 110 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** SHR-1209
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03944109
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-20
- **Primary completion:** 2020-12-22
- **Final completion:** 2020-12-22
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03944109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03944109, "The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03944109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*